ArticleOpen veterinary journal2024
How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
Article in Open veterinary journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Pre-anaesthetic risk assessment and management of dogs with myxomatous mitral valve disease: a spectrum of care narrative review.The Journal of small animal practice · 2026Review
- Rare stability in dogs with myxomatous mitral valve disease: Clinical observations of loop diuretic withdrawal after congestive heart failure.Open veterinary journal · 2026Article
- Clinical Value of Serum Cardiac Troponin I, Trimethylamine N-Oxide (TMAO), and Galectin-3 in Canine Myxomatous Mitral Valve Degeneration: A Preliminary Study.Veterinary sciences · 2026Article
- NT-proBNP versus cardiac troponin-I (cTnI) for the early detection of cardiac diseases in dogs with other cardiographic findings.Open veterinary journal · 2025Article
- Article
- Alteration of clinical parameters before mortality and prognostic outcomes of pulmonary hypertension in dogs with myxomatous mitral valve disease.Open veterinary journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myxomatous mitral valve disease (MMVD) is prevalent in dogs. Specialized diagnostics (radiography and echocardiography) may be unavailable in some veterinary settings. Cardiac biomarkers offer potential alternatives. Aim: This study evaluated the diagnostic value of Methods: 69 dogs with MMVD (asymptomatic and symptomatic) and 19 healthy controls were assessed. Biomarker levels were measured using commercial kit rapid tests. Results: Our results showed that the median NT-proBNP level in the symptomatic group was higher than those in the asymptomatic ( Conclusion: NT-proBNP and cTnI may serve as point-of-care tests for dyspneic dogs, aiding MMVD assessment where specialized diagnostics are limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.